Skip to main content

Market Overview

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY) reporting forecast-beating earnings.

Intec Pharma Ltd (NASDAQ: NTEC) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS) lost much of their market value this week on clinical trial setbacks.

The following are some of the key biotech catalysts in the upcoming week:


  • 2nd Annual Biotechnology Congress: July 29-30 in Chicago.
  • 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden.
  • 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago.

Clinical Trial Readouts (mid-2019 releases)

  • Immunic Inc (NASDAQ: IMUX): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis.
  • Conatus Pharmaceuticals Inc (NASDAQ: CNAT): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
  • Alkermes Plc (NASDAQ: ALKS): Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis.
  • IMMUTEP LTD/S ADR (NASDAQ: IMMP): initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer.
  • Aevi Genomic Medicine Inc (NASDAQ: GNMX): Phase 1b data for AEVI-002 in pediatric onset Crohn's disease.
  • Tricida Inc (NASDAQ: TCDA): 12-month registration stability data from a Phase 3 study of TRC 101 in chronic kidney disease.
  • Curis, Inc. (NASDAQ: CRIS): Phase 1 data for CA-4948 in relapsed or refractory non-Hodgkin lymphoma.
  • Ultragenyx Pharmaceutical Inc (NASDAQ: RARE): Phase 1/2 data from a second cohort that is evaluating its DTX401 in Glycogen storage disease type 1 and Phase 1/2 third cohort data for DTX301 in ornithine transcarbamylase.
  • Allakos Inc (NASDAQ: ALLK): Phase 2 top-line data for AK002 in eosinophilic gastritis.
  • Leap Therapeutics Inc (NASDAQ: LPTXV): Phase 1/2 data for DKN-01 plus Keytruda in esophagogastric adenocarcinoma.
  • Cidara Therapeutics Inc (NASDAQ: CDTX): Phase 2 data for rezafungin in candidemia.
  • Akcea Therapeutics Inc (NASDAQ: AKCA): Phase 3 data for volanesorsen in familial partial lipodystrophy.
  • Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) and Zai Lab Ltd (NASDAQ: ZLAB): Phase 3 data for DCC-2618 from a study dubbed INVICTUS in gastrointestinal stromal tumors
  • ZEALAND PHARMA/S ADR (NASDAQ: ZEAL): Phase 1b data for dasiglucagon in obesity/diabetes.
  • Aclaris Therapeutics Inc (NASDAQ: ACRS): Phase 2 open label 6-month data for ATI-502 in vitiligo and Phase 2 data for ATI-502 in atopic dermatitis.
  • AnaptysBio Inc (NASDAQ: ANAB): Phase 2 data for ANB019 in generalized pustular psoriasis.
  • Spark Therapeutics Inc (NASDAQ: ONCE): additional Phase 1/2 data for SPK-8011 in hemophilia A


Monday, July 29

  • Medpace Holdings Inc (NASDAQ: MEDP) (before the market open)
  • Alimera Sciences Inc (NASDAQ: ALIM) (after the market close)
  • Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the market close)
  • Silk Road Medical Inc (NASDAQ: SILK) (after the market close)

Tuesday, July 30

  • Eli Lilly And Co (NYSE: LLY) (before the market open)
  • Iradimed Corp (NASDAQ: IRMD) (before the market open)
  • Blueprint Medicines Corp (NASDAQ: BPMC) (before the market open)
  • Meridian Bioscience, Inc. (NASDAQ: VIVO) (before the market open)
  • Merck & Co., Inc. (NYSE: MRK) (before the market open)
  • Incyte Corporation (NASDAQ: INCY) (before the market open)
  • Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (before the market open)
  • NeoGenomics, Inc. (NASDAQ: NEO) (before the market open)
  • Pfizer Inc. (NYSE: PFE) (before the market open)
  • Amgen, Inc. (NASDAQ: AMGN) (after the market close)
  • AtriCure Inc. (NASDAQ: ATRC) (after the market close)
  • EXACT Sciences Corporation (NASDAQ: EXAS) (after the market close)
  • T2 Biosystems Inc (NASDAQ: TTOO) (after the market close)
  • BioTelemetry Inc (NASDAQ: BEAT) (after the market close)
  • Gilead Sciences, Inc. (NASDAQ: GILD) (after the market close)
  • Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (after the market close)
  • Veracyte Inc (NASDAQ: VCYT) (after the market close)

Wednesday, July 31

  • Amarin Corporation plc (NASDAQ: AMRN) (before the market open)
  • Strongbridge Biopharma plc (NASDAQ: SBBP) (before the market open)
  • United Therapeutics Corporation (NASDAQ: UTHR) (before the market open)
  • Nuvectra Corp (NASDAQ: NVTR) (after the market close)
  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (after the market close)
  • Exelixis, Inc. (NASDAQ: EXEL) (after the market close)
  • DexCom, Inc. (NASDAQ: DXCM) (after the market close)
  • Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the market close)
  • MacroGenics Inc (NASDAQ: MGNX) (after the market close)
  • Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (after the market close)
  • SurModics, Inc. (NASDAQ: SRDX) (after the market close)

Thursday, Aug. 1

  • Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the market open)
  • Akorn, Inc. (NASDAQ: AKRX) (before the market open)
  • ABIOMED, Inc. (NASDAQ: ABMD) (before the market open)
  • Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the market open)
  • Clovis Oncology Inc (NASDAQ: CLVS) (before the market open)
  • Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open)
  • Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open)
  • Insmed Incorporated (NASDAQ: INSM) (before the market open)
  • Intellia Therapeutics Inc (NASDAQ: NTLA) (before the market open)
  • Genomic Health, Inc. (NASDAQ: GHDX) (after the market close)
  • Acorda Therapeutics Inc (NASDAQ: ACOR) (after the market close)
  • Emergent Biosolutions Inc (NYSE: EBS) (after the market close)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the market close)
  • Coherus Biosciences Inc (NASDAQ: CHRS) (after the market close)
  • Kindred Biosciences Inc (NASDAQ: KIN) (after the market close)
  • Bio-Rad Laboratories, Inc. (NYSE: BIO) (after the market close)
  • Geron Corporation (NASDAQ: GERN) (after the market close)
  • Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the market close)
  • CareDx Inc (NASDAQ: CDNA) (after the market close)
  • Globus Medical Inc (NYSE: GMED) (after the market close)
  • Verastem Inc (NASDAQ: VSTM) (after the market close)
  • Ultragenyx (after the market close)
  • Kura Oncology Inc (NASDAQ: KURA) (after the market close)

Friday, Aug. 2

  • Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) (before the market open)


Rapt Therapeutics, a biotech company developing therapies for inflammatory diseases and cancer, is set to offer 5 million shares at an estimated price range of $14-$16. The company proposes to list its shares on the Nasdaq under the ticker symbol "RAPT."


Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Previews FDA IPOs Top Stories Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at